Pfizer Thelin development (correction)
Executive Summary
Pfizer has commenced enrollment of patients in a Phase III study for Thelin (sitaxsentan) to support a U.S. filing for the treatment of pulmonary arterial hypertension. The "Sitaxentan Efficacy and Safety Trial With a Randomized Prospective Assessment of Adding Sildenafil" (SR-PAAS) is expected to be completed by June 2010. An article in "The Pink Sheet" inaccurately stated that Pfizer was likely to abandon a Thelin NDA (1"The Pink Sheet" Jan. 5, 2009, p. 8)